Jupiter Biomed

Jupiter Biopharm is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative precision medicines for the treatment of cancer and immunological diseases. The company leverages its proprietary drug discovery platform to target well-validated oncogenic drivers and overcome resistance mechanisms in solid tumors. Its lead candidate, JBP-01, is a potent, brain-penetrant EGFR/HER2 inhibitor currently being evaluated in Phase 1/2 clinical trials for patients with advanced non-small cell lung cancer and other solid tumors. Jupiter Biopharm's pipeline also includes a next-generation CDK4/6 inhibitor and a KRAS G12C inhibitor, both designed to offer superior efficacy and safety profiles. With a global presence and a team of experienced industry veterans, the company aims to deliver transformative therapies to patients worldwide.